State Street
KYTX icon

State Street’s Kyverna Therapeutics KYTX Stock Holding History

State Street’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.75M Buy
982,233
+843,933
+610% +$7.49M ﹤0.01% 2751
2026
Q1 		$1.19M Buy
138,300
+47,000
+51% +$392K ﹤0.01% 3450
2025
Q4 		$858K Hold
91,300
– – ﹤0.01% 3557
2025
Q3 		$548K Hold
91,300
– – ﹤0.01% 3644
2025
Q2 		$280K Sell
91,300
-283,278
-76% -$701K ﹤0.01% 3745
2025
Q1 		$723K Sell
374,578
-5,310
-1% -$15.7K ﹤0.01% 3507
2024
Q4 		$1.42M Buy
379,888
+53,696
+16% +$257K ﹤0.01% 3411
2024
Q3 		$1.6M Buy
326,192
+10,244
+3% +$79K ﹤0.01% 3393
2024
Q2 		$2.37M Buy
315,948
+265,548
+527% +$4.06M ﹤0.01% 3256
2024
Q1 		$1.25M Buy
+50,400
New +$1.41M ﹤0.01% 3410

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

State Street's KYTX Position: Q2 2026 in Review

State Street increased its Kyverna Therapeutics (KYTX) stake by 610% in Q2 2026, buying an estimated $7.49M and bringing the position to 982,233 shares worth $8.75M. The position accounts for ﹤0.01% of the portfolio, ranked #2751.

State Street first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • State Street held 982,233 shares of Kyverna Therapeutics worth $8.75M as of Q2 2026.
  • State Street bought 843,933 Kyverna Therapeutics shares in Q2 2026, an estimated $7.49M.
  • Kyverna Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2751 holding.
  • State Street first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.